课题基金 / 基金详情

Lead Optimization and Mechanisms of Action of Dual-Acting Antitrypanosomal Agents

Lead Optimization and Mechanisms of Action of Dual-Acting Antitrypanosomal Agents
双效抗锥虫药物的先导化合物优化及作用机制
批准号:
10655612
负责人:
Ifedayo Victor Ogungbe
金额:
$37.3万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-09 至 2025-06-30

项目摘要

项目成果

Ifedayo Victor Ogungbe的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 致病原生动物导致几种被忽视的、持久的和新出现的热带疾病。这些 疾病影响着全世界数以亿计的人,它们对 全球公共卫生,包括美国的公共卫生。热带病的关键问题 获得有效药物的机会有限、诊断工具不足以及药物开发 病原菌对现有药物的耐药性。因此,继续努力控制、消除、 并提供安全有效的治疗选择至关重要。在这个SC1项目中,我们将努力 致力于研究可作为人类非洲药物线索的新化学物质 锥虫病(HAT)和恰加斯病。主要目的是调查化学物质。 可抑制原虫对临床用寄生虫的耐药性发展 硝基芳香族药物。我们预计,该项目中概述的研究将推动临床前 具有多种作用机制的新一代抗锥虫药物的研究。 此外,我们期待这一项目目的和目的的成功实施 将产生关于抗锥虫药物的创新和基础知识。
英文摘要
Project Summary Pathogenic protozoans cause several neglected, persistent, and emerging tropical diseases. These diseases impact hundreds of millions of people worldwide, and they pose significant threat to global public health, including that of the United States. The key problems of tropical diseases are limited access to effective drugs, inadequate diagnostic tools, and development of drug resistance to existing drugs by the etiological agents. Hence, continued effort to control, eliminate, and provide safe and effective treatment options is crucial. In this SC1 project, our efforts will be devoted to investigating new chemical entities that can serve as drug leads for human African trypanosomiasis (HAT) and Chagas disease. The main objective is to investigate chemical entities that can suppress the development of drug resistance by protozoan parasites to clinically used nitroaromatic drugs. We envision that the studies outlined in this project will propel preclinical studies of new generation antitrypanosomal agents that possess multiple mechanisms of action. In addition, we expect that successful implementation of the aims and objectives of this project will produce innovative and fundamental knowledge on antitrypanosomal agents.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1039/d2ra00423b
发表时间: 2022-04-07
期刊: RSC advances
影响因子: 3.9
作者: []
通讯作者:
DOI: 10.3390/molecules27186005
发表时间: 2022-09-15
期刊: Molecules (Basel, Switzerland)
影响因子: --
作者: []
通讯作者:
Discovery of an orally active nitrothiophene-based antitrypanosomal agent.
发现一种口服活性硝基噻吩类抗锥虫药。
DOI: 10.1016/j.ejmech.2023.115954
发表时间: 2024
期刊: European journal of medicinal chemistry
影响因子: 6.7
作者: [Ajayi,Oluwatomi, Metibemu,DamilohunS, Crown,Olamide, Adeyinka,OlawaleS, Kaiser,Marcel, Shoji,Nathalie, Silva,Mariana, Rodriguez,Ana, Ogungbe,IfedayoVictor]
通讯作者: Ogungbe,IfedayoVictor
Lead Optimization and Mechanisms of Action of Dual-Acting Antitrypanosomal Agents
  • 批准号:
    10172488
  • 项目类别:
  • 资助金额:
    $35.75万
  • 财政年份:
    2021
  • 负责人:
    Ifedayo Victor Ogungbe
  • 依托单位:
Hit to Lead Optimization of Non-Peptidic Inhibitors of Alphaviral Cysteine Protease
  • 批准号:
    10196140
  • 项目类别:
  • 资助金额:
    $18.21万
  • 财政年份:
    2021
  • 负责人:
    Ifedayo Victor Ogungbe
  • 依托单位:
Lead Optimization and Mechanisms of Action of Dual-Acting Antitrypanosomal Agents
  • 批准号:
    10445231
  • 项目类别:
  • 资助金额:
    $36.3万
  • 财政年份:
    2021
  • 负责人:
    Ifedayo Victor Ogungbe
  • 依托单位:
Identification, Optimization and Structural Investigation of Antiprotozoal Agents and Molecular Target
  • 批准号:
    9767240
  • 项目类别:
  • 资助金额:
    $11.33万
  • 财政年份:
    2017
  • 负责人:
    Ifedayo Victor Ogungbe
  • 依托单位:
海外基金